Back to Results

Haemonetics Corporation (HAE)

Haemonetics Corporation is a healthcare equipment and supplies company focused on medical technology solutions for hospitals and specialty care settings in the United States and international markets. As an issuer of common stock listed on the NYSE under the ticker HAE, the company develops systems and software for plasma collection and donor management, including NexSys PCS, PCS2, NexLynk DMS and Donor360. Its broader portfolio also includes hemostasis testing systems such as TEG products and TEG Manager software, Cell Saver Elite+ blood recovery systems, and VASCADE closure products. Haemonetics additionally provides devices and related technologies used in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery and cancer surgery, along with fiber optic sensor solutions used in medical and industrial applications. The company sells through direct sales teams, distributors, clinical specialists and sales representatives. Haemonetics was founded in 1971 and is headquartered in Boston, Massachusetts.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-HAE
$91.59
17.8% Upside
Fair
$86.60
11.4% Upside
Fair
Great
—
—
—
0.0%
August 6, 2026
36.1x
4.4x
2.6x
3.553 B
4.541 B
26.4%
98.7%
3.9
—
267.6%
Send a message
Valuation • Fair Value

Haemonetics Corporation (NYSE-HAE) Fair Value by Valuation Model

Compare the primary fair value estimate for Haemonetics Corporation (NYSE-HAE) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$91.59

Estimated upside of 17.8% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$111.22

Discounted cash flow valuation reference.

Ben Graham Formula Value

$23.76

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$81.77

Comparable-company valuation reference.

Analyst Price Target

$86.60

Analysts imply upside of 11.4%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Haemonetics Corporation (NYSE-HAE) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Haemonetics Corporation (NYSE-HAE)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

1.334 B

Current operating scale indicator.

Revenue Forecast

1.4 B

Forward revenue estimate.

EBITDA

357.2 M

Current operating profitability reference.

EBITDA Forecast

437 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Haemonetics Corporation (NYSE-HAE) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Haemonetics Corporation (NYSE-HAE)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Great

Positive financial-health read.

Piotroski Score

7

Relatively strong quality score.

Beneish M-Score

-2.75

No elevated caution signal from this screen.

Altman Z-Score

3.9

Relatively strong balance-sheet zone.

FCF / Net Income

267.6%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Haemonetics Corporation (NYSE-HAE). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Haemonetics Corporation (NYSE-HAE)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 6, 2026

Days to Earnings

16

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Haemonetics Corporation (NYSE-HAE), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Haemonetics Corporation (NYSE-HAE) Stock Forecast & Technical Outlook

Review Haemonetics Corporation (NYSE-HAE) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Haemonetics Corporation (NYSE-HAE) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Sell

The 1-hour technical read for Haemonetics Corporation (NYSE-HAE) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Haemonetics Corporation (NYSE-HAE) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Haemonetics Corporation (NYSE-HAE) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Haemonetics Corporation (NYSE-HAE) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Haemonetics Corporation (NYSE-HAE)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Buy

Based on the available recommendation mix, Haemonetics Corporation (NYSE-HAE) has a Buy consensus, with 4 buy, 3 hold and 0 sell recommendations in the current data set.

Buy 4
Hold 3
Sell 0
FAQ • Fast Investor Answers

Haemonetics Corporation (NYSE-HAE) Stock FAQ

Quick answers about Haemonetics Corporation (NYSE-HAE) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$91.59
Estimated upside 17.8%
Valuation Rating
Undervalued
Estimated upside of 17.8%
Analyst Target
$86.60
Implied upside 11.4%
Financial Health
Great
Current financial-health read

The current fair value estimate for Haemonetics Corporation (NYSE-HAE) is $91.59. This implies an estimated upside of 17.8% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 17.8% versus the current market price.

The available analyst price target for Haemonetics Corporation (NYSE-HAE) is $86.60. The analyst target implies estimated upside of 11.4%.

The current financial health read for Haemonetics Corporation (NYSE-HAE) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Haemonetics Corporation (NYSE-HAE) is August 6, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Haemonetics Corporation (NYSE-HAE) is 36.1x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Haemonetics Corporation is 3.553 B.

The current enterprise value listed for Haemonetics Corporation is 4.541 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Haemonetics Corporation is NYSE-HAE, and the stock is listed on NYSE.

Haemonetics Corporation (NYSE-HAE) is listed on NYSE.

The current debt-to-total-capital ratio listed for Haemonetics Corporation is 26.4%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Haemonetics Corporation is 98.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks on NYSE View more

Abbott Laboratories (ABT) Abbott Laboratories (ABT)
Stryker Corporation (SYK) Stryker Corporation (SYK)
Medtronic PLC (MDT) Medtronic PLC (MDT)
Boston Scientific Corp (BSX) Boston Scientific Corp (BSX)
Edwards Lifesciences Corp (EW) Edwards Lifesciences Corp (EW)
Becton Dickinson and Co (BDX) Becton Dickinson and Co (BDX)
Alcon AG (ALC) Alcon AG (ALC)
ResMed Inc (RMD) ResMed Inc (RMD)
Koninklijke Philips NV ADR (PHG) Koninklijke Philips NV ADR (PHG)
STERIS plc (STE) STERIS plc (STE)
Zimmer Biomet Holdings Inc (ZBH) Zimmer Biomet Holdings Inc (ZBH)
Solventum Corp (SOLV) Solventum Corp (SOLV)
Smith & Nephew SNATS Inc (SNN) Smith & Nephew SNATS Inc (SNN)
Penumbra Inc (PEN) Penumbra Inc (PEN)
Baxter International Inc (BAX) Baxter International Inc (BAX)
Globus Medical (GMED) Globus Medical (GMED)
Glaukos Corp (GKOS) Glaukos Corp (GKOS)
Teleflex Incorporated (TFX) Teleflex Incorporated (TFX)
Bausch + Lomb Corp (BLCO) Bausch + Lomb Corp (BLCO)
Envista Holdings Corp (NVST) Envista Holdings Corp (NVST)
Integer Holdings Corp (ITGR) Integer Holdings Corp (ITGR)
Butterfly Network, Inc (BFLY) Butterfly Network, Inc (BFLY)
Enovis Corp (ENOV) Enovis Corp (ENOV)
Inspire Medical Systems Inc (INSP) Inspire Medical Systems Inc (INSP)